Get started
Author

Francesca D’Ambrosio

Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD
2025 · Fabrizio Termite, Sebastiano Archilei, et al. · Antioxidants · 48
PDF
Cytokines and Hepatocellular Carcinoma: Biomarkers of a Deadly Embrace
2022 · Krizia Pocino, Annunziata Stefanile, et al. · Journal of Personalized Medicine · 40
PDF
Bioactive Peptides Derived from Edible Insects: Effects on Human Health and Possible Applications in Dentistry
2023 · Gianmaria Fabrizio Ferrazzano, Francesca D’Ambrosio, et al. · Nutrients · 39
PDF
Clinical trials and drug cost savings for Italian health service
2020 · Francesca D’Ambrosio, Gianfranco De Feo, et al. · BMC Health Services Research · 25
PDF
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
2026 · Michael Pavlides, Yasaman Vali, et al. · Nature Medicine · 9
PDF
Distinct Biomarker Profiles of B-Cell Activation in Metabolic and Viral Hepatic Fibrosis
2025 · Umberto Basile, Valeria Carnazzo, et al. · International Journal of Molecular Sciences · 4
PDF
Serum‐free light chains as a dependable biomarker for stratifying patients with metabolic dysfunction‐associated steatotic liver disease
2024 · Antonio Liguori, Francesca D'Ambrosio, et al. · Liver International · 4
PDF
Enhanced Liver Fibrosis Test, FIB ‐4 and FibroScan : Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort
2026 · Antonio Liguori, Francesca D'Ambrosio, et al. · Liver International · 2
Prognostic role of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
2024 · A. Liguori, F. D'Ambrosio, et al. · Digestive and Liver Disease · 2
The Organization of Clinical Trials for Oncology at IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale” Napoli and the Impact of the OECI Accreditation Process
2015 · Gianfranco De Feo, Francesca D'Ambrosio, et al. · Tumori Journal · 2
Multiple Myeloma Measurable Residual Disease: Spotting Three Different Detection Methods
2026 · Sara Tartaglione, Marzia Tagliaferro, et al. · International Journal of Molecular Sciences
Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study
2026 · Yasaman Vali, Kristy Wonders, et al. · The Lancet
Genetic Clues to Advanced Liver Fibrosis In Italian Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
2026 · Nadia Panera, Antonio Liguori, et al. · Digestive and Liver Disease
PDF
Integrated phenotyping of the gut-platelet-liver axis in the progression of MASLD-related chronic liver disease
2026 · Alessandra Pistillo, Antonio Liguori, et al. · Digestive and Liver Disease
PDF
WED-102-YI Artificial intelligence-guided approaches to define biochemical and epigenetic markers that may reflect the metabolic dysfunction-associated steatohepatitis phenotype in children and adults
2026 · Flavia Grignaffini, Maria Rita Braghini, et al. · Journal of Hepatology
WED-261-YI Prognostic significance of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
2024 · Antonio Liguori, Francesca D'Ambrosio, et al. · Journal of Hepatology
T.07.5: the Prognostic Role of the Elf Test, Compared to Liver Biopsy, in Patients With Metabolic Dysfunctionassociated Steatotic Liver Disease (masld)
2024 · A. Liguori, F. D'Ambrosio, et al. · Digestive and Liver Disease
The bidirectional relationship between fatty liver disease and COVID-19
2023 · Antonio Liguori, Valentin Calvez, et al. · Metabolism and Target Organ Damage
PDF
Free light chains: novel serum biomarkers for NASH stratification, an update
2023 · Antonio Liguori, Umberto Basile, et al. · Journal of Hepatology
Validation of elastography criteria and cACLD risk model for diagnosis of compensated advanced chronic liver disease (cACLD) in NAFLD patients
2023 · Antonio Liguori, Mirko Zoncapè, et al. · Journal of Hepatology
Additional file 2 of Clinical trials and drug cost savings for Italian health service
2020 · D’Ambrosio, Francesca, Feo, Gianfranco De, et al. · Figshare
Additional file 3 of Clinical trials and drug cost savings for Italian health service
2020 · D’Ambrosio, Francesca, Feo, Gianfranco De, et al. · Figshare
Additional file 4 of Clinical trials and drug cost savings for Italian health service
2020 · D’Ambrosio, Francesca, Feo, Gianfranco De, et al. · Figshare
Additional file 1 of Clinical trials and drug cost savings for Italian health service
2020 · D’Ambrosio, Francesca, Feo, Gianfranco De, et al. · Figshare
Works count: 24
Citation count: 175
H-index: 5
I10-index: 4
Year
Topic
Type